KIORA PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
KIORA PHARMACEUTICALS, INC. (KPRX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 852.50 thousand shares for the 3-month period ending 2019-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2020-05-06
- KIORA PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2019-03-31 was 852.50K shares.
- KIORA PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2018-03-31 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month as first filed |
|---|---|---|
| 2019-03-31 | 852.50K shares 10-Q · filed 2020-05-06 | 12.79M shares 10-Q · filed 2019-05-08 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |